170 related articles for article (PubMed ID: 37301185)
1. Amelioratory effects of astragaloside IV on hepatocarcinogenesis via Nrf2-mediated pSmad3C/3L transformation.
Fang Gong Y; Hou S; Xu JC; Chen Y; Zhu LL; Xu YY; Chen YQ; Li MM; Li LL; Yang JJ; Yang Y
Phytomedicine; 2023 Aug; 117():154903. PubMed ID: 37301185
[TBL] [Abstract][Full Text] [Related]
2. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways.
Zhang C; Li L; Hou S; Shi Z; Xu W; Wang Q; He Y; Gong Y; Fang Z; Yang Y
J Ethnopharmacol; 2021 Oct; 279():114350. PubMed ID: 34157326
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV suppresses migration and invasion of TGF-β
Li L; Wang Q; He Y; Sun L; Yang Y; Pang X
Naunyn Schmiedebergs Arch Pharmacol; 2022 Apr; 395(4):397-405. PubMed ID: 35092472
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 knockout attenuates the astragaloside IV therapeutic effect on kidney fibrosis from liver cancer by regulating pSmad3C/3L pathways.
Wang Q; Xu J; Li M; Chen Y; Xu Y; Li L; Gong Y; Yang Y
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1687-1700. PubMed ID: 37712971
[TBL] [Abstract][Full Text] [Related]
5. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocellular carcinoma progression via miR-145/miR-21 mediated Smad3 phosphorylation.
Wu C; Chen W; Fang M; Boye A; Tao X; Xu Y; Hou S; Yang Y
J Ethnopharmacol; 2019 Mar; 231():98-112. PubMed ID: 30412748
[TBL] [Abstract][Full Text] [Related]
6. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
[TBL] [Abstract][Full Text] [Related]
7. Smad3 C-terminal phosphorylation site mutation attenuates the hepatoprotective effect of salvianolic acid B against hepatocarcinogenesis.
Gong Y; Li D; Li L; Yang J; Ding H; Zhang C; Wen G; Wu C; Fang Z; Hou S; Yang Y
Food Chem Toxicol; 2021 Jan; 147():111912. PubMed ID: 33290806
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
[TBL] [Abstract][Full Text] [Related]
9. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
[TBL] [Abstract][Full Text] [Related]
10. Salvianolic acid B exerts an anti-hepatocellular carcinoma effect by regulating the Hippo/YAP pathway and promoting pSmad3L to pSmad3C simultaneously.
Xu W; Shi Z; Yu X; Xu Y; Chen Y; He Y; Gong Y; Huang C; Tan C; Yang Y
Eur J Pharmacol; 2023 Jan; 939():175423. PubMed ID: 36509132
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis.
Kawamata S; Matsuzaki K; Murata M; Seki T; Matsuoka K; Iwao Y; Hibi T; Okazaki K
Inflamm Bowel Dis; 2011 Mar; 17(3):683-95. PubMed ID: 20602465
[TBL] [Abstract][Full Text] [Related]
12. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
[TBL] [Abstract][Full Text] [Related]
13. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy.
Kim SH; Ahn S; Park CK
Hepatobiliary Pancreat Dis Int; 2012 Feb; 11(1):51-9. PubMed ID: 22251470
[TBL] [Abstract][Full Text] [Related]
14. Interaction of microRNA-21/145 and Smad3 domain-specific phosphorylation in hepatocellular carcinoma.
Wang JY; Fang M; Boye A; Wu C; Wu JJ; Ma Y; Hou S; Kan Y; Yang Y
Oncotarget; 2017 Oct; 8(49):84958-84973. PubMed ID: 29156696
[TBL] [Abstract][Full Text] [Related]
15. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis.
Matsuzaki K
Histol Histopathol; 2006 Jun; 21(6):645-62. PubMed ID: 16528675
[TBL] [Abstract][Full Text] [Related]
16. Smad3 gene C-terminal phosphorylation site mutation exacerbates CCl
Yang J; Gong Y; Xu W; Li L; Shi Z; Wang Q; He Y; Zhang C; Luo C; Fang Z; Yang Y
Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1779-1786. PubMed ID: 34191114
[TBL] [Abstract][Full Text] [Related]
17. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis.
Suwa K; Yamaguchi T; Yoshida K; Murata M; Ichimura M; Tsuneyama K; Seki T; Okazaki K
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991602
[TBL] [Abstract][Full Text] [Related]
18. Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPK-regulated TGF-β/Smad signaling in hepatocellular carcinoma by multi-target mechanism.
Boye A; Wu C; Jiang Y; Wang J; Wu J; Yang X; Yang Y
J Ethnopharmacol; 2015 Jul; 169():219-28. PubMed ID: 25934513
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C.
Yamaguchi T; Matsuzaki K; Inokuchi R; Kawamura R; Yoshida K; Murata M; Fujisawa J; Fukushima N; Sata M; Kage M; Nakashima O; Tamori A; Kawada N; Tsuneyama K; Dooley S; Seki T; Okazaki K
Hepatol Res; 2013 Dec; 43(12):1327-42. PubMed ID: 23458062
[TBL] [Abstract][Full Text] [Related]
20. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
Murata M; Yoshida K; Yamaguchi T; Matsuzaki K
World J Gastroenterol; 2014 Nov; 20(41):15018-27. PubMed ID: 25386050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
